Amid fears of a malaria epidemic and the spread of polio in Ethiopia, Japan's donation will go a long way. Despite this and other generous new donations, the Ethiopian humanitarian appeal for children remains critically under-funded.

The Government of Japan today donated US$ 5 million to UNICEF to help wipe out polio and prevent an epidemic of malaria across Ethiopia.

The Japanese contribution, the single largest donation to UNICEF for disease prevention programmes in Ethiopi...

Johns Hopkins cardiologists are calling for an expansion of the criteria widely used by physicians to detect and assess a postmenopausal woman's chances of developing cardiovascular disease, the leading cause of death among women in the United States.

In an editorial appearing in the Journal of the American Medical Association (JAMA) online, Roger Blumenthal, M.D., and colleagues say that a family history of heart disease and blood levels of a protein tied to vessel inflammation, C-reac...

A molecule which can stop the formation of long protein strands, known as amyloid fibrils, that cause joint pain in kidney dialysis patients has been identified by researchers at the University of Leeds.

The discovery could lead to new methods to identify drugs to prevent, treat or halt the progression of other conditions in which amyloid fibrils play a part, including Alzheimer's, Parkinson's and Type II diabetes.

The research, funded by the Biotechnology and Biological Scienc...

William R. Jacobs, Jr., Ph.D., professor of microbiology & immunology and of genetics at Albert Einstein College of Medicine of Yeshiva University, who is also a Howard Hughes Medical Institute (HHMI) investigator, has been awarded a three-year, $4 million grant from the National Institutes of Health (NIH) to develop a novel genetic strategy for combating tuberculosis (TB). TB causes almost two million deaths each year, making it the world's most deadly bacterial infection.

In this ambi...

The anti-thrombotic drug ARIXTRA(R) is now indicated for use in patients undergoing abdominal surgery, GlaxoSmithKline [NYSE: GSK] announced today. The U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for ARIXTRA in the prevention of venous thromboembolism (VTE) in patients undergoing abdominal surgery who are at risk of thromboembolic complications.

"Since many patients undergoing abdominal surgery are at high risk of developing VTE, the...

Tag Cloud